ReviewCancers2024
Stereotactic Radiosurgery in Metastatic Spine Disease-A Systemic Review of the Literature.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of stereotactic radiosurgery for petroclival meningiomas: A systematic review and Meta-Analysis.Acta neurologica Belgica · 2026Pooled it
- Treatment outcomes of stereotactic radiosurgery for thyroid cancer spine metastases-systematic review.Neurosurgical review · 2026Pooled it
- Higher Dose Irradiation for Malignant Spinal Cord Compression: Long-Term Results of the RAMSES-01 Trial.Current oncology (Toronto, Ont.) · 2026Trial
- Long-Term Results of a Comparison Between 15 × 2.633 Gy and 20 × 2.0 Gy for Malignant Spinal Cord Compression in Patients with Longer Expected Survival Times.Journal of clinical medicine · 2026Article
- Long-Term Results of a Propensity Score Analysis Comparing 5 × 5 Gy and 10 × 3 Gy of Radiotherapy Alone for Malignant Spinal Cord Compression.Journal of clinical medicine · 2025Article
- Radiotherapy with 5 × 5 Gy for Personalized Treatment of Malignant Epidural Compression of the Myelon: Long-Term Results of the PRE-MODE Trial.Journal of personalized medicine · 2025Article
- Initial Outcomes of Zap-X Stereotactic Radiosurgery for the Treatment of Spinal Tumors: A Case Series.Cureus · 2025Article
- Advancing the potential of nanoparticles for cancer detection and precision therapeutics.Medical oncology (Northwood, London, England) · 2025Review
- Integrated management of metastatic spinal tumors: current status and future directions.Medical oncology (Northwood, London, England) · 2025Review
- The role of multidisciplinary team meetings in the management of spinal tumors.Journal of craniovertebral junction & spineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the efficacy of stereotactic radiosurgery (SRS) in managing spinal metastasis. Traditionally, surgery was the primary approach, but SRS has emerged as a promising alternative.
objectiveThe study aims to evaluate the efficacy of stereotactic radiosurgery in the management of spinal metastasis in terms of local tumor control, patient survival, and quality of life, identifying both advantages and limitations of SRS.
methodsThrough an extensive literature search in PubMed with cross-referencing, relevant full-text-available papers published between 2012 and 2022 in English or German were included. The search string used was "metastatic spine diseases AND SRS OR stereotactic radiosurgery".
resultsThere is growing evidence of SRS as a precise and effective treatment. SRS delivers high radiation doses while minimizing exposure to critical neural structures, offering benefits like pain relief, limited tumor growth, and a low complication rate, even for tumors resistant to traditional radiation therapies. SRS can be a primary treatment for certain metastatic cases, particularly those without spinal cord compression.
conclusionsSRS appears to be a preferable option for oligometastasis and radioresistant lesions, assuming there are no contraindications. Further research is necessary to refine treatment protocols, determine optimal radiation dose and fractionation schemes, and assess the long-term effects of SRS on neural structures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.